Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665970 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3KDM1AMAOBCYP2A13 | |
| SCHEMBL667411 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3KDM1AMAOBCYP2A13 | |
| SCHEMBL73941 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3KDM1AMAOBCYP2A13 | |
| SCHEMBL7118432 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3KDM1AMAOBCYP2A13 | |
| SCHEMBL667276 | 0.79 | L3MBTL1 (0.40) | L3MBTL3ALDH1A1L3MBTL1 | |
| SCHEMBL1664709 | 0.79 | — | — | |
| SCHEMBL477164 | 0.79 | L3MBTL1 (0.40) | L3MBTL3ALDH1A1L3MBTL1 | |
| SCHEMBL667548 | 0.79 | L3MBTL1 (0.40) | L3MBTL3ALDH1A1L3MBTL1 | |
| SCHEMBL1489870 | 0.77 | L3MBTL3 (0.39) | L3MBTL3ALDH1A1L3MBTL1HRH3 | |
| SCHEMBL1489616 | 0.77 | L3MBTL3 (0.39) | L3MBTL3ALDH1A1L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-1888565-B1 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL SA (ES) | 2011-03-23 | — | — | EP | disclosed |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | BET1, PGGT1B, TMPO | SMN1; SMN2 4756/4885L3MBTL3 4885/4885KDM1A 2377/4885 |
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | SMN1; SMN2 4762/4885L3MBTL3 3555/4885KDM1A 4216/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | SMN1; SMN2 4762/4885L3MBTL3 3555/4885KDM1A 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.